ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

BIOLOGICS LICENSE APPLICATION ACCEPTED FOR THE LICENSED PRODUCT FOR THE TREATMENT OF EXUDATIVE (WET) AGE-RELATED MACULAR DEGENERATION

References are made to (i) the announcement of Essex Bio-Technology Limited (the "**Company**") dated 15 October 2020 ("**Announcement**") in relation to the Co-Development License Agreement entered into between the Licensee (both are wholly-owned subsidiaries of the Company) with Shanghai Henlius Biotech, Inc. ("**Henlius**") for the co-development of, and the grant to the Licensee of the exclusive rights relating to, the Licensed Product in accordance with the terms of the Co-Development License Agreement; and (ii) various announcements of the Company published during the period from January 2021 to April 2025 in relation to certain updates thereon. The Licensed Product is a bio-pharmaceutical product that contains the recombinant anti-vascular endothelial growth factor humanised monoclonal antibody ("**anti-VEGF**"), a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration ("**wet-AMD**"). Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

FURTHER UPDATE ON THE DEVELOPMENT RELATING TO HLX04-O

The Board is pleased to announce that a Biologics License Application (BLA) for the anti-VEGF ophthalmic injection bio-pharmaceutical product (referred to as "**HLX04-O**") has recently been accepted by the Centre for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in the PRC.

INFORMATION ABOUT HLX04-O

HLX04-O is a new ophthalmic preparation product developed based on HANBEITAI (bevacizumab injection) independently developed by Henlius, through optimising the prescription, specifications and production processes of HANBEITAI (bevacizumab injection) according to the requirements of ophthalmic drugs, without changing the active ingredients, and is intended to be used for the treatment of wet-AMD.

In addition to the phase 3 clinical study of HLX04-O in Chinese patients with wet-AMD (AURA-1) which has met its primary endpoint in April 2025, an international multi-centre phase 3 clinical study of HLX04-O in patients with wet-AMD is ongoing successively in several European countries, Australia, the United States and the PRC (AURA-2) with last patient last visit completed by January 2025.

CURRENT MARKET CONDITION

As of the date of this announcement, to the best of the Directors' knowledge, there is yet an approved bevacizumab product for the treatment of wet-AMD in the PRC. According to the statistics released by IQVIA CHPA (IQVIA is the world's provider of professional information and strategic consulting services in the pharmaceutical and healthcare industry), sales of drugs approved in the PRC for the treatment of wet-AMD in 2024 were approximately RMB4.9 billion.

The Company cannot guarantee the successful development and commercialisation of HLX04-O. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 13 August 2025

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Ms. Yeow Mee Mooi and Mr. Yan Man Sing Frankie.